바터팽대부암의 치료성적

The Outcomes of Curative Resection for Ampulla of Vater Cancer

  • Kim, Yong-Bae (Department of Surgery, Korea Institute of Radiological and Medical Science) ;
  • Kim, Sang-Bum (Department of Surgery, Korea Institute of Radiological and Medical Science) ;
  • Cho, Eung-Ho (Department of Surgery, Korea Institute of Radiological and Medical Science) ;
  • Choi, Dong-Wook (SungKyunKwan University School of Medicine) ;
  • Bang, Ho-Yoon (Department of Surgery, Korea Institute of Radiological and Medical Science) ;
  • Lee, Jong-Inn (Department of Surgery, Korea Institute of Radiological and Medical Science) ;
  • Moon, Nan-Mo (Department of Surgery, Korea Institute of Radiological and Medical Science)
  • 발행 : 2009.03.25

초록

Introduction: The prognosis of peri-ampullary cancer is poor because of its low respectability and high recurrence rate. Yet cancer of the Ampulla of Vater(AOV) has a relatively good prognosis. The aim of this study is to investigate the outcomes and to determine the factors that affect the survival rate of patients who underwent curative resection for AOV cancer. Methods: From August 1988 to January 2008, 54 patients underwent curative resection for AOV cancer. We retrospectively reviewed the clinocopathologic data. The median follow up period was 45 months. Results: Twenty-seven pancreaticoduodenectomies (PD) and 27 pyrolus-preserving pancreaticoduodenectomies (PPPD) were performed. There was no hospital mortality, but 25 out of 54 patients (47.3%) experienced postoperative complications. The 5-year overall survival (OS) rate was 53.97% and the 5-year disease free survival (DFS) rate was 51.75%. On multivariate analysis, the variables that affected the overall survival rate and the disease free survival rate was poor histologic differentiation (p<0.001). Conclusions: Although the AOV cancer is one of the periampullary cancers that have a very poor outcome, long-term survival and favorable outcomes can be achieved after a curative resection. In this study, poor-histologic differentiation was the only independent factor for a poor prognosis.

키워드

참고문헌

  1. Albores-Saavedra J, Henson DE, Sobin LH. The WHO histological classification of tumors of the gallbladder and extrahe patic bile ducts. A commentary on the second edition. Cancer 1992;70:410-414. https://doi.org/10.1002/1097-0142(19920715)70:2<410::AID-CNCR2820700207>3.0.CO;2-R
  2. Yamaguchi K, Enjoji M. Carcinoma of the ampulla of Vater. A clinicopathologic study and pathologic staging of 109 cases of carcinoma and 5 cases of adenoma. Cancer 1987;59:506-515. https://doi.org/10.1002/1097-0142(19870201)59:3<506::AID-CNCR2820590326>3.0.CO;2-#
  3. Nakase A, Matsumoto Y, Uchida K, Honjo I. Surgical treatment of cancer of the pancreas and the periampullary region: Cumulative results in 57 institutions in japan. Ann Surg 1977;185:52-57. https://doi.org/10.1097/00000658-197701000-00008
  4. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998;228:87-94. https://doi.org/10.1097/00000658-199807000-00013
  5. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: Analysis of 5-year survivors. Ann Surg 1998;227:821-831. https://doi.org/10.1097/00000658-199806000-00005
  6. Perzin KH, Bridge MF. Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma. Cancer 1981;48:799-819. https://doi.org/10.1002/1097-0142(19810801)48:3<799::AID-CNCR2820480324>3.0.CO;2-Q
  7. Seifert E, Schulte F, Stolte M. Adenoma and carcinoma of the duodenum and papilla of Vater: a clinicopathologic study. Am J Gastroenterol 1992;87:37-42.
  8. Yoon DS. Surgery for ampulla of Vater adenoma. Korean J HBP surg 2007;11:1-6.
  9. Monson JR, Donohue JH, McEntee GP, et al. Radical resection for carcinoma of the ampulla of Vater. Arch Surg 1991;126:353-357. https://doi.org/10.1001/archsurg.1991.01410270099016
  10. Allema JH, Reinders ME, van Gulik TM, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995;117:247-253. https://doi.org/10.1016/S0039-6060(05)80197-7
  11. Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: Fifty-five consecutive resections. Arch Surg 2003;138:941,8; discussion 948-950.
  12. Akwari OE, van Heerden JA, Adson MA, Baggenstoss AH. Radical pancreatoduodenectomy for cancer of the papilla of Vater. Arch Surg 1977;112:451-456. https://doi.org/10.1001/archsurg.1977.01370040103016
  13. Yoon YS, Kim SW, Park SJ, et al. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg 2005;242:92-100. https://doi.org/10.1097/01.sla.0000167853.04171.bb
  14. Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg 1997;225:590-599; discussion 599-600. https://doi.org/10.1097/00000658-199705000-00015
  15. Todoroki T, Koike N, Morishita Y, et al. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol 2003;10:1176-1183. https://doi.org/10.1245/ASO.2003.07.512
  16. Shutze WP, Sack J, Aldrete JS. Long-term follow-up of 24 patients undergoing radical resection for ampullary carcinoma, 1953 to 1988. Cancer 1990;66:1717-1720. https://doi.org/10.1002/1097-0142(19901015)66:8<1717::AID-CNCR2820660811>3.0.CO;2-4
  17. Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: The Mayo clinic experience. Int J Radiat Oncol Biol Phys 2006;66:514-519. https://doi.org/10.1016/j.ijrobp.2006.04.018
  18. Mehta VK, Fisher GA, Ford, JM et al. Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report. Arch Surg 2001;136:65-69. https://doi.org/10.1001/archsurg.136.1.65